Logo image
Abstract 19139: Comparative Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin for Intracardiac Thrombus: A Propensity Score-Matched Analysis of 21,368 Patients
Journal article   Peer reviewed

Abstract 19139: Comparative Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin for Intracardiac Thrombus: A Propensity Score-Matched Analysis of 21,368 Patients

Gurparvesh Singh Goraya, Gurkaranvir Singh, Inderjeet Singh Bharaj, FNU Tanvir, Harshan Atwal, Yashendra Sethi, Inderbir Padda and Namit Rohant
Circulation (New York, N.Y.), Vol.154(Suppl_1), pp.A19139-A19139
11/02/2026

Abstract

Direct factor Xa inhibitor Warfarin Anticoagulation Cardiac Thromboembolism Outcomes
Background: Optimal anticoagulation for intracardiac thrombus (ICT) remains uncertain. Warfarin has been standard therapy, yet DOACs are increasingly used off-label despite limited randomized evidence. Prior studies were underpowered or conflicting; whether findings persist in a larger cohort is unknown. Hypothesis: DOAC therapy is associated with comparable or improved thromboembolic and safety outcomes versus warfarin. Methods: We performed a retrospective propensity score-matched analysis using TriNetX. Adults with ICT (ICD-10 I51.3) identified in temporal association with transthoracic echocardiography (CPT 93306-93308) and treated with apixaban, rivaroxaban, or warfarin were included. Matching balanced demographics, cardiovascular comorbidities, heart failure severity, prior MI, cardiogenic shock, atrial fibrillation, prosthetic valves, cirrhosis, CKD, antiplatelet therapy, and guideline-directed medical therapy (all standardized mean differences <0.1). The primary outcome was persistent or recurrent thrombus between 90-180 days. Secondary outcomes through 365 days included ischemic stroke, TIA, arterial embolism, GI bleeding, intracranial hemorrhage, all-cause mortality, and acute MI. Results: After matching, 10,684 patients remained per cohort. DOACs were associated with lower rates of persistent/recurrent thrombus (18.5% vs. 24.2%; HR 0.789, 95% CI 0.744-0.836; p<0.001), arterial embolism (2.0% vs. 3.0%; HR 0.706, 95% CI 0.588-0.846; p<0.001), GI bleeding (3.8% vs. 4.8%; HR 0.854, 95% CI 0.744-0.982; p=0.026), acute MI (8.1% vs. 11.9%; HR 0.708, 95% CI 0.629-0.797; p<0.001), and intracranial hemorrhage (0.9% vs. 1.4%; HR 0.671, 95% CI 0.515-0.875; p=0.003). Ischemic stroke (3.4% vs. 3.6%; HR 1.031; p=0.717) and TIA (1.1% vs. 1.3%; HR 0.914; p=0.920) were similar. Cumulative mortality was similar (17.4% vs. 17.1%; RR 1.016; p=0.608), although time-to-event analysis favored warfarin (HR 1.101, 95% CI 1.032-1.175; p=0.009). Conclusions: In this large propensity score-matched real-world analysis, DOAC therapy was associated with lower rates of persistent or recurrent ICT, arterial embolism, gastrointestinal bleeding, acute MI, and intracranial hemorrhage compared with warfarin, while rates of ischemic stroke and TIA were similar. Although cumulative mortality risk was comparable, time-to-event analysis demonstrated a modest difference favoring warfarin, highlighting the need for prospective validation. Given the observational design and reliance on documented outcomes, these findings should be interpreted as associative rather than causal. Nevertheless, the favorable thrombotic and bleeding profile associated with DOAC therapy supports consideration of DOACs as an alternative to warfarin for ICT and provides a foundation for future randomized trials and guideline development.

Metrics

1 Record Views

Details

Logo image